Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

Time: 9:30 am
day: Day One


  • Sharing insights into future directions and what to anticipate as standards evolve for PARP and other DDRi’s in the clinic
  • How is it looking for prostate? leukemia? GBM? pancreatic? endometrial? SCLC?
  • What are the differences between cancers in terms of resistance to PARP inhibitors?
  • Thoughts on moving to a more genomic rather than indication-specific biomarker-driven treatment strategy?
  • Understanding the hope for the more understudied PARP’s